{"id":309787,"date":"2025-08-10T16:48:13","date_gmt":"2025-08-10T16:48:13","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/309787\/"},"modified":"2025-08-10T16:48:13","modified_gmt":"2025-08-10T16:48:13","slug":"chez-les-femmes-de-plus-de-70-ans-la-chimiotherapie-savere-le-plus-souvent-inutile","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/309787\/","title":{"rendered":"chez les femmes de plus de 70\u00a0ans, la chimioth\u00e9rapie s\u2019av\u00e8re le plus souvent inutile"},"content":{"rendered":"<p>Une grande \u00e9tude fran\u00e7aise vient de d\u00e9montrer qu\u2019elle n\u2019apportait pas de b\u00e9n\u00e9fice significatif en mati\u00e8re de survie dans cette classe d\u2019\u00e2ge en compl\u00e9ment de l\u2019hormonoth\u00e9rapie.<\/p>\n<p class=\"fig-paragraph\">L\u2019avanc\u00e9e en \u00e2ge est un facteur de risque important de\u00a0<a href=\"http:\/\/sante.lefigaro.fr\/medecine\/cancer-du-sein-un-traitement-plus-adapte-quand-la-tumeur-devient-resistante-20250606\" data-fig-type=\"Article\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"SANTE\" rel=\"nofollow noopener\" target=\"_blank\">cancer du sein<\/a>. En Europe, les femmes de plus de 70\u00a0ans repr\u00e9sentent 40\u00a0% des cas. Les essais cliniques qui \u00e9valuent les traitements oncologiques n\u2019int\u00e8grent pourtant que 7\u00a0% \u00e0 10\u00a0% de patientes de cette classe d\u2019\u00e2ge. Une aberration pour le Pr\u00a0\u00c9tienne Brain, oncologue m\u00e9dical \u00e0 l\u2019Institut Curie (Paris et Saint-Cloud) qui, d\u00e8s les ann\u00e9es 2010, a souhait\u00e9 mettre sur pied une \u00e9tude consacr\u00e9e aux patientes \u00e2g\u00e9es afin d\u2019\u00e9valuer l\u2019int\u00e9r\u00eat de certaines th\u00e9rapies sp\u00e9cifiquement dans cette population. Apr\u00e8s plus de dix ann\u00e9es de travail, les r\u00e9sultats de ses travaux viennent d\u2019\u00eatre publi\u00e9s dans la prestigieuse revue m\u00e9dicale The Lancet. \u00ab\u00a0C\u2019est une preuve de reconnaissance internationale de l\u2019importance de cette recherche innovante qui nous apporte des arguments solides pour entamer le dialogue avec nos coll\u00e8gues et avec les patientes\u00a0\u00bb, salue le Dr\u00a0Thomas Bachelot, oncologue sp\u00e9cialiste des cancers du sein au Centre L\u00e9on B\u00e9rard de Lyon\u2026<\/p>\n<p class=\"fig-premium-paywall__infos\">\n        Cet article est r\u00e9serv\u00e9 aux abonn\u00e9s.        Il vous reste 81% \u00e0 d\u00e9couvrir.\n    <\/p>\n<p>                <img  data- alt=\"Le Figaro\" class=\"fig-img--complete fig-img\"\/><\/p>\n<p class=\"fig-premium-paywall__title\">Vous avez envie de lire la suite ?<\/p>\n<p class=\"fig-premium-paywall__subtitle\">D\u00e9bloquez tous les articles imm\u00e9diatement.<\/p>\n<p class=\"fig-premium-paywall__connect\">\n                D\u00e9j\u00e0 abonn\u00e9\u00a0?                <a class=\"fig-premium-paywall__connect-link\" href=\"https:\/\/connect.lefigaro.fr\/login?client=horizon_web&amp;type=main&amp;redirect_uri=https%3A%2F%2Fwww.lefigaro.fr%2Fsciences%2Fcancer-du-sein-hormonodependant-chez-les-femmes-de-plus-de-70-ans-la-chimiotherapie-s-avere-le-plus-souvent-inutile-20250810\" data-js-gtm=\"{&quot;customCategorie&quot;: &quot;conversion&quot;, &quot;customAction&quot;: &quot;before_Landing_Connexion_paywall_auto&quot;, &quot;customLabel&quot;: &quot;bGVmaWdhcm8uZnJfXzFmMDc1ZGQ3LTg5ODgtNjU5Yy04NjJkLWIzYTJjMDU0NjBjNF9fQXJ0aWNsZQ==_Cancer du sein hormonod\u00e9pendant: chez les femmes de plus de 70\u00a0ans, la chimioth\u00e9rapie s\u2019av\u00e8re le plus souvent inutile_1000&quot;, &quot;customIDSPE&quot;: &quot;bGVmaWdhcm8uZnJfXzFmMDc1ZGQ3LTg5ODgtNjU5Yy04NjJkLWIzYTJjMDU0NjBjNF9fQXJ0aWNsZQ==&quot;, &quot;event&quot;: &quot;customEventSPE&quot;}\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n                    Connectez-vous<br \/>\n                <\/a>\n            <\/p>\n","protected":false},"excerpt":{"rendered":"Une grande \u00e9tude fran\u00e7aise vient de d\u00e9montrer qu\u2019elle n\u2019apportait pas de b\u00e9n\u00e9fice significatif en mati\u00e8re de survie dans&hellip;\n","protected":false},"author":2,"featured_media":309788,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[101,1011,27,72,71],"class_list":{"0":"post-309787","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-cancer","9":"tag-fr","10":"tag-france","11":"tag-health","12":"tag-sante"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115005495958857847","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/309787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=309787"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/309787\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/309788"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=309787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=309787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=309787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}